Niraparib resistance management

Niraparib (Niraparib) is a drug commonly used to treat ovarian cancer. It belongs to a class of drugs called PARP (polymerase) inhibitors. However, over time, some patients may develop resistance to niraparib, making the drug less effective in treatment. One strategy to combat resistance is to switch patients to another PARP inhibitor or other treatment. This could avoid drug resistance issues and provide patients with new treatment options.

Combined use with other drugs may help overcome resistance. For example, combining niraparib with chemotherapy drugs or other targeted therapies may produce a synergistic effect and improve treatment effectiveness. The dose of niraparib can be adjusted based on the patient's condition. Sometimes lowering the dose can alleviate resistance problems while still maintaining some therapeutic effect. Participating in clinical trials is a way to explore new treatments and medicines. In clinical trials, new PARP inhibitors, immunotherapies, and other targeted treatments can be tested to find new drugs that are effective against drug resistance. Everyone’s constitution is different and their resistance to drugs is also different. If drug resistance develops after using the drug, please inform your doctor in time and do not adjust the drug dosage yourself.

NiraparibThe original drug has been launched in China and is included in medical insurance, but reimbursement is limited to eligible patients. The price of a common specification100mg*30 capsules per box may be more than 5,000 yuan. The original niraparib drug marketed overseas is more expensive than domestically. There are also generic niraparib drugs produced in other countries. Their pharmaceutical ingredients are basically the same as those of the original niraparib drug sold domestically and abroad. The price of 100mg*30 tablets per box produced by a Bangladesh pharmaceutical factory may be more than 1,000 yuan (the price may fluctuate due to exchange rates).